Agilent Technologies Inc. (NYSE: A) today announced it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as an aid in identifying patients with
triple-negative breast cancer (TNBC) for treatment with KEYTRUDA (pembrolizumab).

PD-L1 expression is a critical biomarker for response to anti-PD-1 therapies such as KEYTRUDA. The expanded use of PD-L1 IHC 22C3 pharmDx strengthens the ability